Merck Licenses SciBrunch Drug, Expands Welireg Kidney Indication, and Withdraws Lung Cancer Filing

SentiSense · Published Sep 28, 2026, 11:04 AM ET · Updated Sep 29, 2026, 8:03 AM ET

MRK licensed SciBrunch's preclinical oral KRAS G12D drug SPR2015 for $400 million upfront and up to $1.73 billion in milestones, taking...